Definitive Contract 75N91025C00020
Award Date
9/15/25
Potential Completion Date
9/14/26
Potential Value
$355K
Federal Agency
National Cancer Institute
Awardee
Cloverleaf Bio, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Hamden, CT 06511, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
55
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
<p>This is a $2,292,085.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Cellectar Biosciences, Inc., a small business, under the Small Business Innovation Research (SBIR) Program. The contract is for the research and development of I-125-CLR1404 as a treatment option for triple-negative breast cancer. The contract has a period of performance through December 31, 2019.</p>
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
This is a Small Business Innovation Research (SBIR) Concept Award issued by the National Cancer Institute, a civilian agency, for the development of therapeutic or preventative technologies to treat or prevent pediatric cancers and/or rare cancers. The $354,957.00 Firm Fixed Price contract was awarded to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, on September 5, 2025, with a completion date of September 4, 2026. The contract is set aside for total small business...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This is a $355,000 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health, to Vcreate, Inc., a minority-owned, self-certified small disadvantaged business. The contract is a Phase I Small Business Technology Transfer (STTR) award that supports the development of T-cell receptors for treating pediatric acute myeloid leukemia. The contract was set aside for small businesses and aims to demonstrate technical...
This is a Phase I SBIR contract award from the National Cancer Institute (NCI) to Tranquility Biodesign LLC, a small business, for the development of a novel engineered bacterial anticancer immunotherapy for Merkel cell carcinoma. The contract, valued at $354,996.00, was awarded under a total small business set-aside solicitation seeking proposals for the development of therapeutic, device, or diagnostic technologies for the treatment, detection, and diagnosis of pediatric cancers and rare...
This $399,951 firm-fixed-price definitive contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the small business Care Progress LLC. The contract supports the development of "BIOMARKERAWARE: A NOVEL SYSTEM TO IMPROVE PRECISION ONCOLOGY" under the NCI's Small Business Innovation Research (SBIR) program, which is a set-aside for small businesses. Care Progress LLC, a for-profit limited liability company, has previously...
<p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a "fibrous scaffold-induced spheroids mimicking TME" solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Transgenex Nanobiotech Inc. The contract is for the development of novel therapeutic agents that target cancer, under SBIR Topic 326. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $1,474,849.83 and an ultimate completion date of July 31, 2019. Transgenex Nanobiotech Inc. is a minority-owned, for-profit...